American Express Announces Election Of Procter & Gamble’s Deborah Platt Majoras To BOD – $AXP $OG $DIA $INVO

By John F. Heerdink, Jr.

As per reports, American Express Company (AXP) announced the appointment of Deborah Platt Majoras to its Board of Directors, effective December 7, 2022. Prior to her retirement earlier this year, Ms. Majoras served as Corporate Secretary & Chief Legal Officer of consumer giant Procter & Gamble Co for 12 years. From 2004 until 2008, she served as Chair of the Federal Trade Commission.

Stephen J. Squeri, Chairman and Chief Executive Officer of American Express stated, “Debbie brings decades of legal, regulatory, and public policy experience to our Board. During her illustrious career, she has counseled global organizations on how to effectively navigate complex operating environments and made lasting impact through her advocacy and implementation of robust consumer protection policies while in government. Her extensive insights and experience will be a significant asset to our Board.“

Dow 30 component American Express Company (AXP) and its subsidiaries provide customers and businesses with charge and credit payment card products and travel-related services globally. They look to enrich the lives of their customers and build business success. To learn more about American Express Company (AXP) and to continue to track its progress please visit the Vista Partners American Express Coverage Page.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

DID YOU KNOW?

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently.